[go: up one dir, main page]

WO1999033980A3 - Members of tnf and tnfr families - Google Patents

Members of tnf and tnfr families Download PDF

Info

Publication number
WO1999033980A3
WO1999033980A3 PCT/US1998/027474 US9827474W WO9933980A3 WO 1999033980 A3 WO1999033980 A3 WO 1999033980A3 US 9827474 W US9827474 W US 9827474W WO 9933980 A3 WO9933980 A3 WO 9933980A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnf
members
proteins
tnfr
tnfr families
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/027474
Other languages
French (fr)
Other versions
WO1999033980A9 (en
WO1999033980A2 (en
Inventor
Catherine Tribouley
David Pot
Altaf Kassam
George Lamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to AU20934/99A priority Critical patent/AU2093499A/en
Publication of WO1999033980A2 publication Critical patent/WO1999033980A2/en
Publication of WO1999033980A9 publication Critical patent/WO1999033980A9/en
Publication of WO1999033980A3 publication Critical patent/WO1999033980A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Members of the TNF and the TNFR superfamily of proteins have been identified. These proteins are promising targets for therapeutic intervention and mimesis. TNF-L and TNFR-L proteins can be used to induce cell death and/or profileration of cells. Members of these superfamilies have been implicated in a broad variety of disease processes, making them central biological and physiological regulators.
PCT/US1998/027474 1997-12-30 1998-12-22 Members of tnf and tnfr families Ceased WO1999033980A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20934/99A AU2093499A (en) 1997-12-30 1998-12-22 Members of tnf and tnfr families

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6895997P 1997-12-30 1997-12-30
US60/068,959 1997-12-30
US21227098A 1998-12-16 1998-12-16
US09/212,270 1998-12-16

Publications (3)

Publication Number Publication Date
WO1999033980A2 WO1999033980A2 (en) 1999-07-08
WO1999033980A9 WO1999033980A9 (en) 1999-10-14
WO1999033980A3 true WO1999033980A3 (en) 1999-11-18

Family

ID=26749548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/027474 Ceased WO1999033980A2 (en) 1997-12-30 1998-12-22 Members of tnf and tnfr families

Country Status (2)

Country Link
AU (1) AU2093499A (en)
WO (1) WO1999033980A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982302B2 (en) 2011-02-28 2018-05-29 Genentech, Inc. Biological markers and methods for predicting response to B-cell antagonists

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
JP2001507937A (en) 1997-01-14 2001-06-19 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Tumor necrosis factor receptor 6α and tumor necrosis factor receptor 6β
EP1012282B1 (en) 1997-09-12 2007-04-18 Biogen Idec MA Inc. Cysteine rich receptors-train
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
JP2002528046A (en) * 1998-01-27 2002-09-03 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド Novel receptor superfamily molecules and their uses
EP1415659B9 (en) 1999-01-25 2012-02-15 Biogen Idec MA Inc. An antibody specific for soluble BAFF for use in the treatment of cancer
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU2574200A (en) * 1999-02-19 2000-09-04 Toshio Kitamura Novel tnf receptor-like proteins
AU777536B2 (en) * 1999-02-23 2004-10-21 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
KR20090016772A (en) 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 BAF receptor (UCMA), immunomodulator
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
DK1666052T3 (en) 2000-02-16 2011-09-12 Genentech Inc Anti-APRIL monoclonal antibody and its use in the treatment of an immune-related disease or cancer
MXPA02010011A (en) 2000-04-11 2003-04-25 Genentech Inc Multivalent antibodies and uses therefor.
ES2287130T3 (en) 2000-05-12 2007-12-16 Amgen Inc. POLYPEPTIDES TO INHIBIT THE PROLIFERATION OF CELLS B AND T INDUCED BY APRIL.
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
ES2317924T3 (en) 2000-07-27 2009-05-01 Genentech, Inc. SEQUENTIAL ADMINISTRATION OF CPT-11 AND APO-2L POLYPEPTIDE.
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
EP1401870A4 (en) 2001-05-24 2006-04-19 Human Genome Sciences Antibodies against tumor necrosis factor delta (april)
ATE433996T1 (en) 2001-07-03 2009-07-15 Genentech Inc HUMAN DR4 ANTIBODIES AND THEIR APPLICATIONS
DE10221018A1 (en) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
EP2272868B1 (en) 2003-06-05 2015-03-04 Genentech, Inc. Combination therapy for B cell disorders
JP2008505607A (en) 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド BCMA extracellular domain variants and methods of use thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
WO2006041680A2 (en) 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
RU2492864C2 (en) 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Method of treating cancer carrying egfr mutations
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
LT2451445T (en) 2009-07-06 2019-06-25 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
EP2473637B1 (en) 2009-09-03 2017-03-29 F. Hoffmann-La Roche AG Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
EP0869180A1 (en) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation A TNF homologue, TL5
WO1998055620A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998055621A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999012964A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Kay - a novel immune system protein

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO1998018921A1 (en) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
EP0869180A1 (en) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation A TNF homologue, TL5
WO1998055620A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1998055621A1 (en) * 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999012964A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Kay - a novel immune system protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGGARWAL B.B. AND NATARAJAN K.: "Tumor necrosis factor: developments during the last decade", EUROPEAN CYTOKINE NETWORK, vol. 7, no. 2, April 1996 (1996-04-01) - June 1996 (1996-06-01), pages 93 - 124, XP002094503 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002101204, Database accession no. AA682496 *
GRUSS H.-J. AND DOWER S.K.: "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas", BLOOD, vol. 85, no. 12, 15 June 1995 (1995-06-15), pages 3378 - 3404, XP002094502 *
GRUSS H.-J.: "Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily", INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH, vol. 26, no. 3, 1996, pages 143 - 159, XP002094504 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982302B2 (en) 2011-02-28 2018-05-29 Genentech, Inc. Biological markers and methods for predicting response to B-cell antagonists

Also Published As

Publication number Publication date
WO1999033980A9 (en) 1999-10-14
WO1999033980A2 (en) 1999-07-08
AU2093499A (en) 1999-07-19

Similar Documents

Publication Publication Date Title
WO1999033980A3 (en) Members of tnf and tnfr families
WO2000060079A3 (en) New members of tnf and tnfr families
Scanlon et al. Cisplatin resistance in human cancers
CA2063427A1 (en) Rapid, versatile and simple system for expressing genes in eukaryotic cells
ATE231509T1 (en) 1,5-DIHYDRO-PYRAZOLO 3,4-D)-PYRIMIDINONE DERIVATIVES
ATE237312T1 (en) NUCLEIC ACID COMPLEXES ENCAPSULATED IN LIPOSOMES
CA2005016A1 (en) Dna fragment containing promoter region for human polypeptide chain elongation factor-1.alpha. and expression plasmid containing the dna fragment
NZ297537A (en) method for changing the cell characteristics of the female reproductive tract
GR3015015T3 (en) Leukocyte poor red blood cell storage system.
AU716500B2 (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
WO2004056868A3 (en) Nf-hev compositions and methods of use
IL135911A0 (en) Dna 19355 polypeptide, a tumor necrosis factor homolog
EP0525917A3 (en) Double-stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles
AU7437900A (en) Cryopreserved amniotic human cells for future therapeutic, diagnostic, genetic and others uses
IT1241123B (en) HUMAN CELLS FOR THE HIGH EXPRESSION OF GENES INSERTED IN DNA EPISOMIAL RECOMBINANTS, THEIR PREPARATION AND THEIR USE
Das et al. Blood polyamine in schizophrenia
Copeland et al. Regional localization of three convertases, PC1 (Nec-1), PC2 (Nec-2), and furin (Fur), on mouse chromosomes
Konstantinović et al. Nuclear matrix from resting and concanavalin A-stimulated human lymphocytes
Pool et al. Zygote intrafallopian transfer with" donor rescue": a new option for severe male factor infertility
MD1119G2 (en) Method for female genitals inflammatory diseases treatment
DE3853112D1 (en) DNA molecules which encode placental bovine lactogen peptide and the pre-peptide and genetically transformed cells which contain these molecules.
Guglielmi et al. Prevalence of monoclonal Ig with λ light chains in chronic myelocytic leukaemia
Katakura et al. The Presence of Protein Disulfide Isomerase in the Yeast Saccharomyces cerevisiae
WO2001051509A3 (en) Shc-associated protein 140 (sap-140)
Kahn Commentary on Zohar's" Prospects for'genetic therapy'--can a person benefit from being altered?

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase